COURT OF APPEAL (CIVIL DIVISION)
ON APPEAL FROM CHANCERY DIVISION
MR JUSTICE LAWRENCE COLLINS
Strand, London, WC2A 2LL | ||
B e f o r e :
LORD JUSTICE BUXTON
and
LORD JUSTICE CARNWATH
____________________
iSOFT GROUP PLC | Appellant | |
- and - | ||
MISYS HOLDINGS LIMITED MISYS PLC | Respondent |
____________________
Smith Bernal Wordwave Limited, 190 Fleet Street
London EC4A 2AG
Tel No: 020 7421 4040, Fax No: 020 7831 8838
Official Shorthand Writers to the Court)
Mr Andrew Onslow QC and Mr Orlando Fraser (instructed by Allen and Overy) for the Respondent
____________________
AS APPROVED BY THE COURT
Crown Copyright ©
Lord Justice Carnwath :
Introduction
Clause 11
"(10) Clause 11.1 defines the expression "Restricted Person" to include any member of the "Seller's Group," which means Holdings, any subsidiary undertaking or parent undertaking of Holdings and any subsidiary for the time being of a parent undertaking of Holdings (clause 1.1) (i.e. it included after acquired subsidiaries).
(11) By clause 11.2.1 Holdings undertook to iSOFT that without the latter's written consent:
"... for a period of 3 years from Completion it will not and will procure that no other Restricted Person will in any capacity whatsoever directly or indirectly carry on or assist in carrying on or be engaged, concerned or interested in any activity or undertaking which is the same as, or substantially similar to, the business of the Company or any Group Company as carried on at the date of this Agreement or at Completion ('Restricted Business') within the Restricted Area ..."
(12) The "Company" and "Group Company" meant ACT and its subsidiaries (clause 1.1). The Restricted Area was the UK, South Africa, Poland, Ireland, Kenya, Switzerland and Zimbabwe (clause 11.1).
(13) Clauses 11.2.2, 11.2.3, and 11.2.4 contained provisions prohibiting for three years the solicitation by the Misys group of customers, suppliers and employees. Clause 11.2.5 prohibited the future use by any Restricted Person of the trade names associated with the business carried on by ACT.
(14). By Clause 11.4 nothing in clauses 11.2.1 (three year restrictive covenant) and 11.2.2 (three year non-solicitation of customers) was to prevent any Restricted Person from acquiring any interest in any entity "which carries on a Restricted Business in the UK" provided that the number of employees employed in the UK in the Restricted Business did not exceed 20 per cent of the total number of employees employed in the entity acquired, and by clause 11.4.2
"... the Seller shall procure that relevant Restricted Person shall within 3 months of the completion of the acquisition of the entity offer to sell to the Buyer that part of the acquired entity which carries on a Restricted Business ('Target Business') for a consideration equal to the then fair market value of such business and otherwise on such detailed terms and conditions which are fair and reasonable to both the relevant Restricted Person and the Buyer. The Buyer shall and the Seller shall procure that the relevant Restricted Person shall negotiate in good faith to agree and complete such sale and purchase as soon as is practicable if the Buyer indicates that it wishes to acquire the Target Business. The Seller shall procure that all information and documents reasonably necessary to enable the Buyer to consider the offer and the business and assets the subject of the offer are made available to the Buyer and that all reasonable requests for further access to information, property or personnel are complied with. If the Buyer declines to buy the Target Business, the Restricted Person shall be free to dispose of it on no worse terms to it than it proposed or negotiated with the Buyer (or in relation to the consideration, in the absence of a proposal by the Restricted Person relating thereto, on terms no worse than the fair market value thereof)."
Sunquest and Europa
"(19) The main products of Sunquest were FlexiLab (an integrated pathology system), FlexiRad (a radiology information system) and FlexiMed (a pharmacy information service). The Sunquest acquisition expanded Misys' US healthcare activities from physician and home healthcare systems into hospitals.
(20) Since 1994 Sunquest had a subsidiary, Sunquest Europa Limited ("Europa"). Europa promoted, sold and supported Sunquest IT products in the UK, Ireland and Denmark, and was seeking contracts elsewhere in Europe and also in the Middle East, where it had had some success.
(21) The UK business was a very small part of Sunquest (fewer than 10 employees out of a total of about 800). It occupied serviced offices in West Sussex. It relied entirely on Sunquest for the supply of product, and was dependent on Sunquest for administrative support and customer service functions….
(23) As a wholly-owned subsidiary of Sunquest, Europa did not have any formal licensing, distribution, customer support and service or royalty arrangements with Sunquest. Europa distributed the three product lines, and Sunquest had to approve all sales orders.
(24) Europa was established to compete in Europe, but it had no defined territory for its operation, and it was also soliciting customers in the Middle East. It had substantial laboratory and radiology contracts for hospitals and health services in Ireland and Denmark, and one of its employees was based in Denmark to provide support for Europa's Danish clients. It had also been appointed vendor of choice for a substantial contract with the Department of Health in Dubai.
(25) It paid its parent company the equivalent of a 50% royalty on the licence fees it received from customers….
According to a "company overview" supplied by Misys to iSOFT -
"Europa is essentially a frontline sales and support entity in Europe."
Negotiations for acquisition of Europa
"(37) At the meeting it is clear that it was recognised that in commercial terms the most significant aspect of the acquisition of Europa or its business was the continuation of the arrangements between Sunquest and Europa…. Mr Batra (Misys) confirms that iSOFT indicated at the meeting that they preferred that the bulk of the consideration be reflected in royalty payments from Europa to Sunquest rather than in a price for the shares. At the meeting iSOFT indicated that it was looking for a deal similar to that which it had concluded with a US healthcare company, Eclipsys (which involved the acquisition of a licence to use intellectual property belonging to a US corporation)."
Subsequent negotiations revealed substantial differences between the parties, in particular as to the terms of the proposed licence to be granted by Sunquest to an iSOFT-owned Europa.
"(54)…What had to be offered was that part of the acquired entity which carried on a restricted business, and that was Europa. So that what ought to be sold was the issued shares of that company and putting in place new licensing arrangements was not permissible, and they should be informed what licensing arrangements were in place between Sunquest and Europa at the time when Misys had acquired Sunquest."
This view was not accepted by Misys' solicitors, who wrote on December 10th to explain their client's position–
"that it had complied with the process set out in the agreement, that iSOFT had declined to purchase Europa, and that the process was terminated."
"(61) By the time the negotiations broke down, the position of the parties on the main points at issue (most of which related to the proposed licence) may be summarised as follows:
(a) there was agreement on the products to be licensed: FlexiLab, FlexiRad and FlexiMed;
(b) the territory: the negotiations extended beyond the Restricted Area as defined in the Agreement: they encompassed exclusive rights in the Restricted Area, and non-exclusive rights in other areas: for the latter, Misys proposed Europe and iSOFT suggested Australia, Hong Kong, Singapore and New Zealand; on December 20 Misys proposed that the non-exclusive territories be Europe (other than those in the Restricted Area) and the Middle East. iSOFT's February 20 proposal was exclusive rights in the Restricted Area plus the Scandinavian countries, and non-exclusive rights for the rest of Europe, and that was agreed;
(c) consideration for the share capital of Europa: iSOFT's offer on October 15 was £2.5 million in cash for the share capital and the licence; on December 20 Misys suggested £5 million in cash at completion, and that iSOFT would be able to off-set against this the first £2.5 million of any royalties; on February 20 iSOFT suggested a consideration equal to the net assets of the business, and that became the agreed position;
(d) advance royalty payments: Misys' opening position was that there should be £10 million at the outset and £6 million on the third anniversary, and on each subsequent anniversary of the licence, the preceding year's advance royalty payment plus 15%; iSOFT's opening position was that £2.5 million should represent the consideration for the share capital as well as an advance payment for the first 3 years. Ultimately iSOFT offered a guaranteed minimum payment of £5 million covering the first 3 years (but without any provision for an advance payment); Misys agreed, subject to it being paid in cash on completion, but iSOFT wanted to leave the precise timing to be discussed, and that remained open;
(e) term of licence: 7 years was agreed
(f) royalty rates: Misys' position was that the appropriate royalty was 50% of the licence fees received by Europa; iSOFT initially proposed lower rates, but 50% was later agreed;
(g) obligation to promote Sunquest products as the only like products: initially this was required by Misys and not agreed by iSOFT; on December 20 Misys proposed that from March 1, 2004 for the remainder of the 7 year term, Europa's rights in the exclusive territories would remain exclusive for such time as Europa promoted the products as its primary like products for new business, but ultimately it was agreed that iSOFT's retention of exclusivity in that period would be dependent on maintaining an agreed minimum royalty."
"(28) Following a policy first adopted in 1999, in late January 2002 all companies in Misys' Healthcare division participated in the worldwide re-branding exercise by which they were brought under Misys Healthcare Systems brand name, and now use the Misys logo. Misys' webpage says that what were once Medic, Sunquest and Homecare Information Systems are now Misys Healthcare Systems, which is a division of Misys.
(29) Sunquest has changed its name to Misys Hospital Systems Inc, and Medic Computer Systems LLC has changed its name to Misys Physicians Systems LLC, but I shall use former names to avoid confusion. In March and April 2002 Europa solicited business for Sunquest products at trade fairs in Harrogate and Dublin under the Misys Healthcare Systems brand-name and logo, and referred to Misys Healthcare Systems as "formerly Sunquest Information Systems." It also accepts that Sunquest and Europa (as Misys Healthcare Systems) placed an advertisement for a UK based employee for Europa."
(1) Whether there had been a failure by Misys to comply with Clause 11.4.2 and if so whether specific performance should be awarded ("the specific performance issue").
(2) Whether Misys was in breach of clause 11.2 and if so whether an injunction should be awarded ("the injunction issue").
The Specific Performance Issue
"(68) ….the meaning of the first sentence of clause 11.4.2, and in particular whether it requires that the offer should be capable of acceptance so as to give rise to a contract for the sale of the Target Business; whether it is sufficiently certain to be specifically enforced, and whether the court can now supply the machinery to determine the fair market value and other terms and, if so, what that machinery should be."
He summarised the relevant authorities relating to "uncertainty of terms", in terms which have not been criticised, and which it is unnecessary to repeat. As he rightly recognised:
"(76) The starting point is the rule that in each case it is a question of the true construction of the agreement, and the relevant terms will be construed, if at all possible, to give them the necessary certainty: Hillas & Co Ltd v. Arcos Ltd (1932) 147 LT 503, 512, 514, 517. Particularly where a contract has been partially executed (especially in a commercial contract over a long period) there is a very strong tendency for the courts to imply any reasonable term so as to give effect to their intentions."
"(112) I do not consider that the parties to the Agreement could reasonably be taken to have envisaged that the clause 11.4.2 process would have begun with the presentation to the buyer of a full grown offer capable of acceptance so as to create an immediately binding contract (i.e. with nothing other than the buyer's signature required to conclude an agreement), and it would not occur to a businessman that it should…"
"(113) I am satisfied that the structure of clause 11.4.2 confirms that the word "offer" in the first sentence does not mean "offer capable of acceptance." In my judgment it means an indication by Misys of a willingness to sell at a fair market value and on terms and conditions which are fair and reasonable to both parties. If it means offer in the sense of indication of willingness to sell, then the rest of the clause hangs together and makes sense. After an offer in this sense, iSOFT may indicate that "it wishes to acquire" the Target Business.
(114) This is the natural reaction to an indication of a willingness to sell, and contrary to the idea that it was envisaged that prior to this process iSOFT might accept the offer so as to create a concluded contract. All that is envisaged is that iSOFT and the relevant Restricted Person shall negotiate in good faith to agree and complete the sale. In the course of that process Holdings procures that all documents and information necessary to enable iSOFT to consider "the offer and the business and assets the subject of the offer" are made available. There is no reason to conclude that the word "offer" is used in a different sense here from that in the first sentence. The third sentence makes complete sense in the context of a negotiation. It makes little commercial sense in the context of iSOFT considering a full offer capable of acceptance. The fourth sentence speaks of freedom to dispose of the Target Business on no worse terms than those "proposed" or "negotiated" with iSOFT. The word "proposed" is consistent with proposals made in the context of a negotiation and does not fit with a process beginning with a firm offer capable of acceptance. This is also strikingly supported by the fact that the fourth sentence envisages that the final stage may have been reached without a proposal by the Restricted Person in relation to the consideration."
"(116) They would have known that a sale transaction typically involved the seller offering the business, the provision of information, negotiation to reach provisional agreements on basic terms, due diligence, the preparation of a detailed draft contract, negotiations over the details, the conclusion of a sale contract, often at a meeting at which remaining disagreements are resolved, and completion. It is only necessary to glance at the ACT Agreement (including 30 pages of warranties) to see how complex a sale of shares in a technology company can be."
(121) In the present case Europa had only about 1 per cent of the combined employee strength of the Sunquest group, but the Agreement envisaged that the Target Business might be employing up to 20% of the total work force of the acquired entity. Accordingly, the Target Business might be very substantial. The Target Business might be a separate UK company owned by the acquired entity, or it might be a branch of a Belgian or Australian company. Some of its employees, including senior staff, might be working both in the Restricted Area and outside it. Its head office functions might be separately centred in the Restricted Area, or they might be inextricably linked with those of the acquired entity. Even if the Target Business were carried on by a separate entity substantially centred in the Restricted Area, part of its business might be outside the Restricted Area.
(122) The Target Business would be likely to have continuing obligations to the National Health Service or to the private sector, and their equivalents in other parts of the Restricted Area. If it were a subsidiary of a foreign company, the parent company might have given guarantees. The purchaser of the Target Business would need to be satisfied of continuity of supply from the acquired entity. The vendor would need to be satisfied that it would be indemnified by the purchaser for any guarantees it might have given. If the Target Business depended on its overseas parent or overseas head office for the long-term supply of its products, then that relationship would need a formal contractual structure in the event of a sale."
"(123) Against that background, in my judgment it is a wholly uncommercial reading of clause 11.4.2 to interpret it to mean that the relevant Restricted Person is to make an offer which is immediately capable of acceptance. Commercial common sense dictates that the vendor will indicate a willingness to sell, and perhaps also set out some basic terms, but it is absolutely inherent in the process that the detail, sometimes involving important questions of principle (such a cap on warranty liability, or a contractual time-limit for claims) will have to be reserved for the negotiation process. Consequently, my conclusion is that the first two sentences of clause 11.4.2 have to be read together, and that what they amount to is that "the parties agree to negotiate in the hope of effecting a … contract" (Hillas & Co Ltd v. Arcos Ltd (1932) 147 LT 503, 515)."
"… then no further question arises on this part of the case since iSOFT accepts that if offer does not mean offer capable of acceptance, then the first two sentences of clause 11.4.2 are simply an unenforceable agreement to negotiate and agree."
However, on the footing that he was wrong on that issue, and that "offer" did mean offer capable of acceptance, he was satisfied that it was "so uncertain that it cannot be enforced, whether by specific performance or otherwise". He accepted Misys' submission that the court was being asked, not simply to give certainty to an existing term of an existing contract, but to "write an entire draft contract in a complex field". In particular, he noted that :
(129)…the court would have to establish the "fair market value" of a company which is the exclusive distributor of products and services in a situation where its distribution agreement/licence has no fixed term, where the royalty it will pay is not determined, and where the quantities it may order are not agreed…."
Furthermore, the task could not be simply the valuation of the shares of Europa:
"(132)… The court would have to construct a complete contract from scratch, working out on a term by term basis what term is fair and reasonable to both parties. There is no manageable standard by which the fairness and reasonableness "to both the relevant Restricted Person and the Buyer" can be set or measured other than what is actually acceptable to both parties."
"(135)…the first two sentences of clause 11.4.2 can be (and probably were) complied with; and… in any event clause 11.4.2 is not wholly devoid of legal effect, since the obligation to supply information in the third sentence and conditions on disposal in the fourth sentence to third parties are enforceable."
"Do (the words) provide a standard by which the Court is enabled to ascertain the subject matter of the contract, or do they involve an adjustment between the conflicting interests of the parties, which the parties have left unsettled and on which the Court is not entitled to adjudicate?" (p513).
On balance he agreed with the majority that they fell into the former category.
The injunction issue
"(96)…. Misys accepts that the group's activities amount to assisting Europa in carrying out its business. It points out that on at least two occasions (September 18, and December 12) Mr Batra told Mr Whiston (iSOFT) that Misys would continue to manage the business actively, including the pursuit of sales leads) and that Mr Whiston took no objection. Misys and Sunquest personnel assisted Europa in securing the WLPC contract, and Sunquest guaranteed Europa's obligations under the contract. Europa solicited business for Sunquest products at trade fairs in Harrogate and Dublin under the Misys Healthcare Systems brand-name and logo. Europa is now part of Misys Healthcare Systems and is required and entitled to present and promote itself as such. Sunquest directors were appointed to the board of Europa."
If sub-clause 11.2 is taken as it stands, there has clearly been a breach of the covenant not to "carry on or assist in carrying on" a business substantially similar to that of ACT. That is not in dispute.
"(100) iSOFT accepts therefore that Europa as the Target Business was to be free to carry on its business in the ordinary way. This is implicit in clause 11.4.2. But this does not lead to the conclusion that there is any wider permission for any other Restricted Person to assist Europa in carrying on its business. Such a conclusion would conflict with the opening words of clause 11.4 and is not in any sense necessary to give efficacy to the Agreement."
Before us Mr Cohen accepts that this formulation needs to be modified to the extent that not only Europa, but also Sunquest as the "acquired entity", must be free to carry on its business in the ordinary way, and to that extent assist Europa. Accordingly, his proposed injunction includes an additional proviso as follows:-
"Provided that this order shall not prevent…
(iv) any company which immediately before completion of the acquisition of (Sunquest) by (Misys) was the parent or ultimate parent of Europa from giving any assistance of the type which it gave at or prior to that time."
Misys's submission was that the business of Europa had been "continued in the ordinary way of business", and that the Misys Group members had "done nothing more than is normal for a parent and other group companies to do", that being implicitly permitted by clause 11.4.
"(139) I consider that for present purposes the key word in the opening expression of clause 11.4 is "nothing". In my judgment, it goes further than simply allowing the acquisition of an interest in an entity part of which carries on a Restricted Business. If iSOFT is right, the UK branch will be "that part of the acquired entity which carries on a Restricted Business," but the acquired entity will be a Restricted Person and will not be able to assist or be engaged in the carrying on of the business. A local subsidiary may need credit from a bank and the bank may require a parent company guarantee or letter of comfort; it may need supplies from its parent; it may need head office function. If iSOFT is right the parent company would not be able to assist. To read clause 11 as preventing that assistance in the case of branches and subsidiaries would be uncommercial and unrealistic, and I do not consider that it can reasonably be interpreted in that sense.
(140) Accordingly, my conclusion is that since clause 11.4.2 (as is agreed) allows the business to be carried on, it envisages that the Target Business and the relevant Restricted Person would maintain the ordinary relationship of a business and its owner, and (where applicable) of parent and subsidiary, and accordingly the business could be carried on in the ordinary course. That conclusion is reached either by a process of interpretation of the opening words of clause 11.4.2 or by necessary implication."
"(141) … Europa's business as at the time of acquisition by Misys was the promotion and supply of Sunquest's products to existing and future clients in Europe. That business necessarily involved competing with iSOFT, adopting its parent branding, and depending almost entirely on its parent to carry on its business (by way of technical, marketing, product, and administrative support). Sunquest executives assisted Europa to obtain the WLPC contract by meeting and discussing it and its products; and executives of Misys and the new management of Sunquest endeavoured to give comfort to WLPC about the takeover by Misys and the possible sale to iSOFT.
Lord Justice Buxton :
Lord Justice Simon Brown